Shots: The ODD is based on Omeros’ P-III program assessing OMS721 in patients with HSCT-TMA. Additionally, OMS721 is being evaluated in ongoing P-III program for IgA nephropathy, and aHUS respectively With the above designation OMS721 will serve in both prevention and treatment of HSCT-TMA in EU and the US. OMS721 also received ODD in IgA […]Read More
